B3GALT1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: B3GALT1

NCBI ID: G8708

B3GALT1

B3GALT1: A Potential Drug Target and Biomarker for Various Diseases

B3GALT1 (B3GT1_HUMAN), a protein that belongs to the B3GALT gene family, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns make it an attractive target for researchers to study and develop new treatments.

The B3GALT gene family is a member of the GT-尾 family, which is known for its role in cell signaling pathways. The B3GALT1 protein is a 21-kDa transmembrane protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle. It is characterized by its N-terminal extracellular domain, which contains a unique farnesylated cysteine residue, as well as its C-terminal transmembrane domain and a unique N-terminal tail region.

One of the key features of B3GALT1 is its ability to interact with various signaling pathways, including the TGF-β pathway, which plays a crucial role in cell growth, differentiation, and survival. The TGF-β pathway is a well-established target for many diseases, including cancer, and B3GALT1 may be a valuable drug or biomarker for these diseases.

In addition to its potential role in the TGF-β pathway, B3GALT1 has also been shown to play a role in several other signaling pathways, including the NF-kappa-B pathway and the PI3K/AKT pathway. These pathways are involved in various cellular processes that are important for human health and disease, including inflammation, stress resistance, and metabolism.

The B3GALT1 protein has also been shown to play a role in several diseases, including cancer. For example, studies have shown that B3GALT1 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This increased expression of B3GALT1 may contribute to the development and progression of these diseases.

In addition to its potential role in cancer, B3GALT1 has also been shown to be involved in neurodegenerative diseases. For example, studies have shown that B3GALT1 is overexpressed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This increased expression of B3GALT1 may contribute to the development and progression of these diseases.

Furthermore, B3GALT1 has also been shown to be involved in autoimmune disorders. For example, studies have shown that B3GALT1 is overexpressed in various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. This increased expression of B3GALT1 may contribute to the development and progression of these disorders.

In conclusion, B3GALT1 is a unique and highly expressed protein that has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of B3GALT1 in these diseases and to develop new treatments.

Protein Name: Beta-1,3-galactosyltransferase 1

Functions: Beta-1,3-galactosyltransferase that transfers galactose from UDP-alpha-D-galactose to substrates with a terminal beta-N-acetylglucosamine (beta-GlcNAc) residue. Involved in the biosynthesis of the carbohydrate moieties of glycolipids and glycoproteins. Inactive towards substrates with terminal alpha-N-acetylglucosamine (alpha-GlcNAc) or alpha-N-acetylgalactosamine (alpha-GalNAc) residues

The "B3GALT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B3GALT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets